Recombinant cytomegalovirus vaccine

US5552143A · kind A · utility

Assignees

• The Wistar Institute of Anatomy and Biology · US
• The United States of America, as represented by the Department of Health and Human Services · US

Inventors

• Stanley A. Plotkin · Doylestown, US
• Robert P. Ricciardi · Philadelphia, US
• Ewa Gonczol · Rosemont, US
• Klara Berencsi · Rosemont, US
• Robert F. Rando · Beaconsfield, CA

Key dates

• Filing date: Dec 2, 1994
• Grant date: Sep 3, 1996
• Expiry date: Dec 2, 2014

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2810/6018
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention provides a non-defective adenovirus recombinant expression system for the expression of the HCMV gB subunit, an immunogenic fragment of the gB subunit, and for the expression of non-structural immediate-early exon 4 proteins, said recombinant HCMV-expressing adenovirus being useful as a vaccine.